Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

546
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
546

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complex Deep Neural Networks for Denoising Ultra-Fast Submillimeter T2*-weighted Imaging and Quantitative Susceptibility Mapping.

European journal of radiology artificial intelligence·2026
Same author

Multiple sclerosis as an asynchronous neuroinflammatory system.

Frontiers in immunology·2026
Same author

Investigating the treatment of vascular risk with simvastatin in secondary progressive multiple sclerosis: analysis from the MS-STAT2 randomized controlled trial.

Brain communications·2026
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

The clinical, radiological and genetic spectrum AARS2-related leukoencephalopathy: a case series of 15 patients and review of the literature.

Journal of neurology·2026

Related Experiment Video

Updated: Jul 2, 2025

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.1K

Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges.

Jeremy Chataway1, Thomas Williams2, Vivien Li3

  • 1Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK; Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK; National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK.

The Lancet. Neurology
|February 16, 2024
PubMed
Summary

Treating progressive multiple sclerosis (MS) remains challenging. New drugs and trial designs offer hope for slowing MS disability progression, emphasizing collaborative research for patient-relevant outcomes.

More Related Videos

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.0K
Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
08:48

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

16.8K

Related Experiment Videos

Last Updated: Jul 2, 2025

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.1K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.0K
Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
08:48

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

16.8K

Area of Science:

  • Neurology
  • Clinical Trials
  • Drug Development

Background:

  • Progressive multiple sclerosis (MS) disability continues despite existing disease-modifying treatments.
  • Current treatments for progressive MS are limited, mainly for active inflammatory disease.
  • Interrupting complex pathological processes in progressive MS remains a significant challenge.

Purpose of the Study:

  • To review recent advancements in treating progressive multiple sclerosis.
  • To discuss emerging therapeutic strategies and clinical trial methodologies.
  • To highlight the importance of collaboration in future progressive MS research.

Main Methods:

  • Review of recent immunomodulatory approvals for progressive MS.
  • Discussion of ongoing clinical trials for new drug classes (e.g., Bruton tyrosine-kinase inhibitors).
  • Exploration of neuroprotective compounds and remyelination strategies in clinical trials.
  • Examination of novel clinical trial designs (e.g., multi-arm multi-stage) and intermediate outcome measures.

Main Results:

  • Several immunomodulatory drugs approved since 2014 show modest effects in progressive MS.
  • New drug classes and neuroprotective agents are progressing through clinical trials.
  • Innovative remyelination approaches and efficient trial designs are under investigation.

Conclusions:

  • Despite progress, effective interruption of progressive MS pathology is ongoing.
  • Emerging therapies and optimized trial designs are crucial for advancing progressive MS treatment.
  • Collaboration among stakeholders is vital for generating patient-relevant results in progressive MS research.